SAN FRANCISCO: Gilead Sciences Inc shares fell as first-quarter sales of its antiviral treatments for hepatitis C and HIV failed to meet analysts’ expectations.
Truvada, a treatment for HIV, was the biggest disappointment, while Epclusa and Sovaldi for viral liver disease also fell short of analysts’ projections. Gilead fell 2.4% to $66.92 at 6.37pm in New York after US markets closed.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
